Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease

Exclusion Criteria

• •1. Atypical or secondary parkinsonian syndromes (e.g., Parkinson-plus syndromes, hereditary parkinsonism, drug-induced parkinsonism, etc.).
• •2. Contra-indications to surgery, or any prior intracranial procedure such as deep-brain stimulation, pallidotomy, or other extrapyramidal surgery, or any other neurosurgical intervention deemed by the investigator to interfere with study participation.
• •3. Previous neuroimaging revealing structural brain abnormalities, cerebral vascular malformations, intracranial tumors, risk of intracranial hemorrhage, traumatic brain injury, or other significant findings.
• •4. Mini-Mental State Examination (MMSE) score \< 24.
• •5. Patient Health Questionnaire-9 (PHQ-9) score ≥ 16.
• •6. Abnormal hepatic or renal function: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 1.5 × upper limit of normal (ULN), or serum creatinine (Cr) \> 1.5 × ULN.
• •7. Coagulation disorders or current use of anticoagulants.
• •8. Positive screening for infectious diseases:
• •* Hepatitis B surface antigen (HBsAg) or Hepatitis B virus DNA (HBV-DNA) positive;
• •* Hepatitis C virus RNA (HCV-RNA) positive;
• •* Human immunodeficiency virus (HIV) positive;
• •* Positive syphilis serology.
• •9. Currently receiving antiviral therapy for hepatitis B or C.